Double target for tumor mass destruction.
Saharinen
Pipsa
P
Molecular/Cancer Biology Laboratory, Haartman Institute, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
Alitalo
Kari
K
D016228:Endothelial Growth Factors / Q000235:genetics / Q000378:metabolism; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism; D008222:Lymphokines / Q000235:genetics / Q000378:metabolism; D009369:Neoplasms / Q000098:blood supply* / Q000473:pathology / Q000503:physiopathology; D009389:Neovascularization, Pathologic; D020574:Proto-Oncogene Proteins c-sis / Q000378:metabolism; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*; D017154:Stromal Cells / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D020574:Proto-Oncogene Proteins c-sis; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D020797:Receptor, Platelet-Derived Growth Factor beta; D040262:Receptors, Vascular Endothelial Growth Factor